InSite Vision announced that patient enrollment has begun in the Phase 3 clinical trial of AzaSite Plus and DexaSite for the treatment of blepharitis.
Prosensa has been granted two patents for exon-skipping by the Japanese Patent Office and the U.S. Patent and Trademark Office.
Scientists from the Genomics Institute of the Novartis Research Foundation and The Scripps Research Institute discovered a family of chemical compounds that could lead to a generation of anti-malarial drugs capable of alleviating symptoms and preventing the disease.
Kimble Chase disposable centrifuge tubes are made from borosilicate glass in compliance with ASTM Specification E438, Type I, Class A or B, and capable of withstanding a relative centrifugal force of 2,980.
G-Biosciences' G-Capsule is a electro-elution device for rapid recovery of PCR products, DNA fragments, and proteins from agarose and polyacrylamide gels. The G-Capsule method eliminates additional steps that involve washing, spinning, heating or precipitation.
NVIDIA announced that four applications for material-science and biomolecular modeling—LAMMPS, GROMACS, GAMESS, and QMCPACK—have added support for multiple GPU acceleration, enabling them to cut simulation times from days to hours.
Results from a meta-analysis of cardiovascular safety data from 14 Phase 2b/3 trials in adult patients with type 2 diabetes showed that dapagliflozin was not associated with an unacceptable increase in cardiovascular risk.
A team of researchers has shown that Mycobacterium tuberculosis and several of its close relatives exploit a family of host enzymes known as ABL-family tyrosine kinases to gain entry into host cells and to survive once inside.
A panel of federal health experts voted overwhelmingly to recommend that Pfizer's best-selling vaccine be approved for a new use in preventing pneumococcal disease in adults age 50 and older.
Researchers say a novel combination of a specific sugar molecule with a pair of cell-killing drugs prompts a wide variety of cancer cell types to kill themselves, a process called apoptosis or programmed cell death.
Pfizer Inc. said that European Union regulators approved its drug Vyndaqel as a treatment for transthyretin familial amyloid polyneuropathy, a potentially fatal genetic condition.
Amid pressure from activists, Johnson & Johnson said that it is continuing efforts to remove traces of two harmful chemicals from its baby products around the world.
In its latest report, The Case for Personalized Medicine, the Personalized Medicine Coalition documents the growth of commercially available personalized medicine products from 13 in 2006 to 72 currently.
Genzyme presented positive results from a Phase 2 trial to evaluate the effect of weekly injections of mipomersen on low-density lipoprotein cholesterol in high-risk patients intolerant to statins.
In 2011,, Boehringer Ingelheim made more than $350 million in capital investments throughout its U.S. operations expanding drug discovery, development and manufacturing capabilities.